873537-32-7

Basic information

• Product Name: trans-1-(Boc-aMino)-4-cyanocyclohexane, 97%
• Synonyms: trans-1-(Boc-aMino)-4-cyanocyclohexane, 97%;tert-Butyl trans-4-cyanocyclohexylcarbamate;(4-Cyano-cyclohexyl)-carbaMic acid tert-butyl ester;tert-Butyl (4-cyanocyclohexyl)carbaMate;Carbamic acid, (trans-4-cyanocyclohexyl)-, 1,1-dimethylethyl ester
• CAS NO: 873537-32-7
• Molecular Formula: C₁₂H₂₀N₂O₂
• Molecular Weight: 224.2994
• Mol File: 873537-32-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: trans-1-(Boc-aMino)-4-cyanocyclohexane, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: trans-1-(Boc-aMino)-4-cyanocyclohexane, 97%(873537-32-7)
• EPA Substance Registry System: trans-1-(Boc-aMino)-4-cyanocyclohexane, 97%(873537-32-7)

Safety Data

• HazardClass: 6.1
• Hazardous Substances Data: 873537-32-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Trans-1-(Boc-aMino)-4-cyanocyclohexane, 97% is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure and reactivity enable the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Trans-1-(Boc-aMino)-4-cyanocyclohexane, 97% is used as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties allow for the creation of effective compounds that can protect crops and enhance agricultural productivity.
Used in Research Applications:
Trans-1-(Boc-aMino)-4-cyanocyclohexane, 97% is utilized in research settings for the exploration of new chemical reactions and the development of innovative synthetic pathways. Its high purity level of 97% ensures reliable results and accurate data in experimental studies.
Used in Organic Chemistry:
Trans-1-(Boc-aMino)-4-cyanocyclohexane, 97% serves as a key building block in organic chemistry, contributing to the synthesis of complex organic molecules and the advancement of chemical knowledge. Its unique properties facilitate the development of novel compounds with potential applications in various industries.

Upstream product

• 75-65-0 tert-butyl alcohol 
• 53292-90-3 trans-4-(tert-butoxycarbonylamino)cyclohexanoic acid 
• 643067-91-8 1,1-dimethylethyl [trans-4-(aminocarbonyl)cyclohexyl]carbamate 

Downstream Products

• 1198163-55-1 trans-4-aminocyclohexanecarbonitrile trifluoroacetic acid salt 
• 1198163-38-0 2-((trans)-4-cyanocyclohexyl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide 
• 873651-89-9 (1r,4r)-4-aminocyclohexanecarbonitrile 

Relevant articles and documents

NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF

The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic di

3-oxoisoindoline-1-carboxamides: Potent, state-dependent blockers of voltage-gated sodium channel nav1.7 with efficacy in rat pain models

The voltage-gated sodium channel NaV1.7 is believed to be a critical mediator of pain sensation based on clinical genetic studies and pharmacological results. Clinical utility of nonselective sodium channel blockers is limited due to serious adverse drug effects. Here, we present the optimization, structure-activity relationships, and in vitro and in vivo characterization of a novel series of NaV1.7 inhibitors based on the oxoisoindoline core. Extensive studies with focus on optimization of Na V1.7 potency, selectivity over NaV1.5, and metabolic stability properties produced several interesting oxoisoindoline carboxamides (16A, 26B, 28, 51, 60, and 62) that were further characterized. The oxoisoindoline carboxamides interacted with the local anesthetics binding site. In spite of this, several compounds showed functional selectivity versus Na V1.5 of more than 100-fold. This appeared to be a combination of subtype and state-dependent selectivity. Compound 28 showed concentration- dependent inhibition of nerve injury-induced ectopic in an ex vivo DRG preparation from SNL rats. Compounds 16A and 26B demonstrated concentration-dependent efficacy in preclinical behavioral pain models. The oxoisoindoline carboxamides series described here may be valuable for further investigations for pain therapeutics.

THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: -CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].